ArticleIBRO neuroscience reports2025
Effect of perampanel in reducing depression in patients with focal epilepsy.
Article in IBRO neuroscience reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High prevalence of depression is very common in epilepsy. This study aimed to discover the effect of perampanel on depression in patients with focal epilepsy. Methods: This is a prospective observational study. We included a total of 68 patients with focal EP, which were treated with perampanel. We analyzed data before perampanel treatment and at 6 and 12 months of follow-up of the optimal dose. Using the Beck Depression Inventory-II (BDI-II) scale to evaluate depression, the Mini-Mental State Examination (MMSE) to assess the cognitive function, and the Quality of Life in Epilepsy-31 items (QOLIE-31) to estimate the quality of life of EP patients. Results: The BDI-II score improved significantly compared to before treatment and at 6 and 12 months of follow-up (P < 0.001). The mean total QOLIE-31 score significantly increased from 82.9 ± 20.4 to 88.7 ± 21.2 at the 12-month follow-up (P < 0.001). In addition, seizure control was improved significantly at 12 months: 32.1 % of patients were seizure-free, and 73.2 % were responsive. Moreover, there was statistical relationship between improvement in depression and seizure control. The MMSE score was not different before and after treatment (P > 0.05). Multiple Regression Analysis was found that annual family income, etiology, the frequency of attacks in recent years, types of ASMs and the age were the influence factors of pirampanel in reducing depression ( Conclusion: Perampanel reduced depression symptoms in patients with focal epilepsy, although the lack of a control group or the relatively small sample size.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.